1. Novo Nordisk Fortifies Wegovy's Lead as Eli Lilly's New Obesity Pill Enters the Arena
Novo Nordisk is moving aggressively to defend its dominant position in the lucrative obesity drug market, following the record-breaking launch of its Wegovy pill. The pharmaceutical giant now faces a direct competitive threat as rival Eli Lilly & Co. prepares to launch its own weight-loss pill, aiming to capture a shar...